Abstract:Objective To observe the clinical efficacy of Zhang’s cutting therapy combined with cetirizine hydrochloride in treating chronic spontaneous urticaria (CSU) and its impacts on inflammatory response and immune function. Methods Sixty-four patients with CSU who met the inclusion criteria were randomly assigned to 2 groups, with 32 cases in each group. The trial group received Zhang’s cutting therapy combined with cetirizine hydrochloride, while the control group received cetirizine hydrochloride monotherapy. After 4 weeks of treatment, the clinical efficacy was assessed according to the Chinese guidelines for the diagnosis and treatment of urticaria (2018 edition), and the overall response rate was calculated ([number of markedly improved patients+number of effective patients]/total number of patients×100%). Disease control and activity were evaluated using the urticaria control test (UCT) and urticaria activity score (UAS), respectively. Serum levels of total immunoglobulin (Ig)E, C reactive protein (CRP), eosinophil percentage, complements 3 and 4 (C3 and C4), and peripheral blood T lymphocyte subsets (CD4+, CD8+ and CD4+/CD8+) were compared between the 2 groups. Patients were followed up for 6 months to document recurrence among those with marked improvement or effective response. Results A total of 60 patients were included in the final analysis. The overall response rate was 93.33% (28/30) in the trial group and 66.67% (20/30) in the control group, with the trial group showing a significantly higher response rate than the control group (P=0.023). After treatment, UCT scores increased and UAS scores decreased in both groups compared with baseline (both P<0.001), with the trial group showing higher UCT scores and lower UAS scores than the control group post-treatment (both P<0.001). CRP levels decreased in the trial group but increased in the control group compared with baseline (both P<0.05), and post-treatment CRP levels were lower in the trial group than in the control group (P<0.001). No significant changes were observed in serum total IgE levels, eosinophil percentage, C3, C4, CD4+, and CD4+/CD8+ in either group after treatment, with no significant between-group differences (all P>0.05). During the 6-month follow-up, the recurrence rate was significantly lower in the trial group than in the control group (3.57% [1/28] vs 45.00% [9/20], P<0.05). Conclusion For patients with CSU, Zhang’s cutting therapy combined with cetirizine hydrochloride demonstrates superior clinical efficacy to cetirizine hydrochloride monotherapy by reducing CRP levels and achieving a lower recurrence rate.